AQST Aquestive Therapeutics Inc
Company Analysis
Latest News
Aquestive Bets Its Future on a Postage-Stamp-Sized Allergy Drug — But Can $160 Million in Fresh Capital Buy an FDA Yes?
Shares of Aquestive Therapeutics surged 9.3% in pre-market trading to $4.63, as investors renewed their focus on two financing deals designed to bankroll the...
🟢 Aquestive Therapeutics is trading 9.3% up today following SEC filing for warrant share resale
Aquestive Therapeutics is trading 9.3% up at $4.63 in pre-market sessions, following an SEC filing on July 9, 2026, for the registration of 230,271 warrant...
🔴 AQST is trading 5.1% down today as FDA setbacks and fraud lawsuits weigh on sentiment
AQST is trading at $4.17 (5.1% down) as investors remain cautious following regulatory and legal challenges surrounding its oral allergy drug, Anaphylm. •...
🔴 AQST is trading 5.2% down today as stalled FDA trajectory and lawsuits weigh on sentiment
AQST is trading at $4.24 (5.2% down) as the stock continues to slide following a sharp drop on June 25, 2026, driven by regulatory and legal concerns. •...
Aquestive's Allergy Drug Stalls at the FDA While Lawsuits Pile Up — Can Investors Afford to Wait for a Turnaround?
Shares of Aquestive Therapeutics sank another 11.6% to $4.41 on June 25, extending a brutal stretch for a company whose entire investment case hinges on a...
🔴 AQST is trading 11.6% down today on FDA deficiencies and fraud litigation overhangs
AQST is trading 11.62% down at $4.41 as the stock faces a renewed selloff tied to FDA-identified deficiencies in its Anaphylm NDA and ongoing securities-fraud...
🔴 AQST is trading 5.6% down today, extending weakness from the previous session
AQST is trading 5.6% down at $4.71 in pre-market, extending the weakness seen in the June 24 after-hours session as regulatory and legal overhangs persist. •...
🔴 AQST makes sharp 11.0% drop
AQST is trading at $4.44, down 11.0% versus the comparison close of $4.99 during after-hours. This is a price-movement alert; no separate company-specific...
🔴 AQST is trading 5.6% down today as a director sells over $125k in stock
• AQST is trading 5.6% down at $4.71 in after-hours sessions following a close of $4.99 on June 24, 2026. • The decline follows news of director Julie Krop...
🟢 Aquestive Therapeutics Inc is trading 5.2% up today on continued momentum and broader market gains
Aquestive Therapeutics Inc is trading 5.2% up at $4.66 on continued recent momentum and a positive broader market backdrop. • No fresh company-specific news,...
🟢 Aquestive Therapeutics Inc is trading 5.6% up today amid a broader market rally and rebound from recent weakness
Aquestive Therapeutics Inc is trading 5.6% up today at $4.21, rebounding from recent weakness and extending this week’s modest gains amid a broader risk-on...
🔴 Aquestive Therapeutics Inc is trading 5.1% down today amid broad market sell-off following strong U.S. jobs data
Aquestive Therapeutics Inc is trading at $3.93 (5.1% down) today, moving broadly in line with a sharp market-wide risk-off slump triggered by...
🟢 AQST is trading 7% up today in thin pre-market trading with no clear catalyst
AQST is trading at $4.30 (+7%) in pre-market sessions, rising from its $4.02 close on May 29, 2026, despite a lack of company-specific news. • The price...
🟢 AQST is trading 7% up today in thin pre-market trading
AQST is trading at $4.30 (+7%) in pre-market session, gapping higher despite no company-specific news or clear catalyst. • The stock rose from its previous...
🟢 AQST is trading 14% up today on a $150M refinancing and positive FDA feedback for Anaphylm
AQST is trading at $4.75 (+14%) as investors react to a $150 million refinancing deal and constructive FDA feedback regarding its Anaphylm treatment. • The...
🔴 AQST is trading 10% down today on profit-taking following a post-earnings rally
AQST is trading at $4.25, down 10% as the stock gives back a portion of yesterday’s double-digit post-earnings gains. * The company reported strong Q1 results...
🔴 AQST is trading 7.1% down today on profit-taking after post-earnings surge
AQST is trading at $4.39 (7.1% down) as investors take profits following a sharp 14.53% rally triggered by strong Q1 earnings results. • The stock surged...
Aquestive Therapeutics Eyes $10 Target, Citing On-Track Anaphylm FDA Filing
Citizens reiterated its Market Outperform rating for Aquestive Therapeutics. The analyst maintained a $10 price target for the stock. Citizens expressed...
🔴 AQST is trading 5.3% down today on profit-taking after earnings-driven rally
AQST is trading about 5.3% down at $4.48 in pre-market, giving back part of its 14.53% surge from the May 14 close at $4.73. • The stock previously jumped...
🟢 AQST is trading 12.83% up today on strong Q1 revenue growth and a $150M refinancing deal
AQST is trading 12.83% up at $4.66 after reporting Q1 2026 revenue of $14.4 million—a 66% year-over-year increase—and announcing a major $150 million...